Bone Biologics Corporation Stock
Equities
BBLG
US0980705018
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.53 USD | +0.66% | -4.97% | -66.15% |
Mar. 01 | Bone Biologics Corporation Reports Progress with NB1 Clinical Program | CI |
Feb. 21 | Bone Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.35M |
---|---|---|---|---|---|
Net income 2024 * | -8M | Net income 2025 * | -8M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.05
x | P/E ratio 2025 * |
-0.05
x | Employees | 2 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.85% |
1 day | +0.66% | ||
1 week | -4.97% | ||
Current month | -28.17% | ||
1 month | -27.14% | ||
3 months | -57.02% | ||
6 months | -65.11% | ||
Current year | -66.15% |
Managers | Title | Age | Since |
---|---|---|---|
Jeffrey Frelick
CEO | Chief Executive Officer | 59 | 15-08-16 |
Deina Walsh
DFI | Director of Finance/CFO | 60 | 14-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Stroever
BRD | Director/Board Member | 75 | 11-12-31 |
Don Hankey
CHM | Chairman | 81 | 18-07-15 |
Robert Gagnon
BRD | Director/Board Member | 49 | Jan. 07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.53 | +0.66% | 28,507 |
24-04-25 | 1.52 | -0.33% | 15,177 |
24-04-24 | 1.525 | -4.68% | 60,412 |
24-04-23 | 1.6 | 0.00% | 26,532 |
24-04-22 | 1.6 | -0.62% | 20,809 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.15% | 1.35M | |
+12.07% | 128B | |
-9.04% | 10.65B | |
+0.91% | 8.82B | |
+16.72% | 7.19B | |
+25.15% | 4.99B | |
+7.17% | 3.4B | |
-1.36% | 3.03B | |
-8.73% | 2.14B | |
-10.15% | 2B |
- Stock Market
- Equities
- BBLG Stock